Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
A pathology test that uses artificial intelligence could be used to examine prostate cancer samples and predict which patients are likely to relapse after surgery, a study shows. The test, ... Read more
A combination of surgery and radiation therapy is better at extending the survival of men with locally advanced prostate cancer than radiation therapy plus hormone therapy, but is associated with ... Read more
Patients with castration-resistant prostate cancer (CRPC) who are at high risk for developing metastasis may safely add Erleada (apalutamide) to androgen deprivation therapy without worrying about their quality of life, a ... Read more
Trovagene will soon begin patient recruitment for its Phase 2 clinical trial evaluating PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). The ... Read more
MDxHealth recently signed an agreement that gives it the worldwide licensing rights to manufacture and market its prostate cancer prognostic test that uses Philips‘ recently validated biomarker PDE4D7. MDxHealth will start ... Read more
Janssen’s medication Zytiga (abiraterone) was recently rejected as a first-line treatment for newly diagnosed advanced prostate cancer on the National Health Service (NHS) in England following an initial draft recommendation from the National ... Read more
IsoPSA, a blood test developed by Cleveland Diagnostics that detects cancer-derived PSA, is more accurate in diagnosing prostate cancer than a conventional PSA test and reduces the need for biopsies by ... Read more
Biotechnology company CellCentric recently raised $26 million in private funding to advance clinical testing of its first-in-class therapy candidate CCS1477 as a treatment for prostate cancer. CCS1477 addresses the growing population ... Read more
A new web-based support program could help reduce the psychological stress that affects prostate cancer survivors, a recent study concluded. The program was created by researchers and clinicians at the U.K.’s University ... Read more